leadf
logo-loader
viewHumanigen, Inc.

Humanigen completes patient enrollment for Phase 1 ifabotuzumab brain cancer study

The primary goal of the Phase 1 trial is to evaluate the safety of ifabotuzumab and to recommend a dose for a potential Phase 2 study, either with ifabotuzumab or an antibody drug conjugate based on ifabotuzumab

Brain cancer scan picture
GBM is the most frequent and lethal type of primary brain cancer, with only 10% of patients surviving five years

Humanigen Inc (NASDAQ:HGEN) (FRA:0KB2) has completed patient enrollment in its Phase 1 bioimaging study of ifabotuzumab to treat recurrent brain cancer -  glioblastoma multiforme (GBM). 

The primary goal of this Phase 1 trial is to evaluate the safety of ifabotuzumab and to recommend a dose for a potential Phase 2 study, either with ifabotuzumab or an antibody drug conjugate (ADC) based on ifabotuzumab. 

READ: Humanigen creates Australian entity to help drive Asia-Pacific growth

GBM is the most frequent and lethal type of primary brain cancer, with only 10% of patients surviving five years.

Humanigen's trial is located at the Olivia Newton-John Cancer Research Institute in Victoria, Australia and results are expected in the first half of 2021. It is supported by funding from the Cure Brain Cancer Foundation.

"The study has now completed recruitment and we are very excited at having shown that ifabotuzumab is able to target the brain tumor in all the patients tested without binding to healthy tissue," said Professor Hui Gan, the clinical research lead, in a statement.

"We saw some signs that ifabotuzumab was affecting the blood vessels that feed the tumors and may halt their ability to grow in some patients."

Humanigen is developing its portfolio of clinical and pre-clinical therapies for treating cancers and infectious diseases via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms.

In a separate statement, Humanigen said that its management will present and host meetings with investors and potential partners at the J.P. Morgan Healthcare Conference, held virtually from January 11 to 14, 2021.

Contact the author at giles@proactiveinvestors.com

Quick facts: Humanigen, Inc.

Price: - -

OTCMKTS:HGEN
Market: OTCQB
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Humanigen chosen by National Institute of Health's upcoming coronavirus...

Humanigen Inc (OTCQB:HGEN) CEO Cameron Durrant tells Proactive that its lead drug candidate lenzilumab was selected for use in the National Institute of Health’s upcoming coronavirus trial. Durrant says lenz will be evaluated in the National Institute of Allergy and Infectious Diseases’...

on 07/31/2020

2 min read